Related Articles
Identification of favorable subgroups for alternative anti‑androgen therapy in castration‑resistant prostate cancer
Effect of dutasteride on castration‑resistant prostate cancer
Phase Ⅱ trial of granulocyte-macrophage colony-stimulating factor plus thalidomide in older patients with castration-resistant prostate cancer
Clinical predictor of survival following docetaxel‑based chemotherapy
Effective oral combination metronomic chemotherapy with low toxicity for the management of castration-resistant prostate cancer